HCM
BMRN icon

Hayman Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hayman Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-129,501
Closed -$13.6M – 5
2015
Q3 		$13.6M Buy
129,501
+119,615
+1,210% +$16M 6.3% 6
2015
Q2 		$1.35M Buy
+9,886
New +$1.23M 0.16% 36

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Hayman Capital Management's BMRN Position: Q4 2015 in Review

Hayman Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2015, closing a stake of 129,501 shares — an estimated $13.6M sold.

Hayman Capital Management first reported a position in BMRN in Q2 2015 and held it in 2 quarters. The position peaked at $13.6M in Q3 2015. 389 funds tracked by Wall St. Rank hold BMRN as of Q4 2015.

  • Hayman Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Hayman Capital Management sold 129,501 BioMarin Pharmaceuticals shares in Q4 2015, an estimated $13.6M.
  • Hayman Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Hayman Capital Management's BioMarin Pharmaceuticals position peaked at $13.6M in Q3 2015.
  • 389 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2015.

Based on Hayman Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.